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and The COPDGene® InvestigatorsAbstract
Background: Chronic bronchitis (CB) has been related to poor outcomes in Chronic Obstructive Pulmonary Disease
(COPD). From a clinical standpoint, we have shown that subjects with CB in a group with moderate to severe
airflow obstruction were younger, more likely to be current smokers, male, Caucasian, had worse health related
quality of life, more dyspnea, and increased exacerbation history compared to those without CB. We sought to
further refine our clinical characterization of chronic bronchitics in a larger cohort and analyze the CT correlates of
CB in COPD subjects. We hypothesized that COPD patients with CB would have thicker airways and a greater
history of smoking, acute bronchitis, allergic rhinitis, and occupational exposures compared to those without CB.
Methods: We divided 2703 GOLD 1–4 subjects in the Genetic Epidemiology of COPD (COPDGene®) Study into two
groups based on symptoms: chronic bronchitis (CB+, n = 663, 24.5%) and no chronic bronchitis (CB-, n = 2040,
75.5%). Subjects underwent extensive clinical characterization, and quantitative CT analysis to calculate mean wall area
percent (WA%) of 6 segmental airways was performed using VIDA PW2 (http://www.vidadiagnostics.com). Square roots
of the wall areas of bronchi with internal perimeters 10 mm and 15 mm (Pi10 and Pi15, respectively), % emphysema, %
gas trapping, were calculated using 3D Slicer (http://www.slicer.org).
Results: There were no differences in % emphysema (11.4 ± 12.0 vs. 12.0 ± 12.6%, p = 0.347) or % gas trapping (35.3 ±
21.2 vs. 36.3 ± 20.6%, p = 0.272) between groups. Mean segmental WA% (63.0 ± 3.2 vs. 62.0 ± 3.1%, p < 0.0001), Pi10
(3.72 ± 0.15 vs. 3.69 ± 0.14 mm, p < 0.0001), and Pi15 (5.24 ± 0.22 vs. 5.17 ± 0.20, p < 0.0001) were greater in the CB +
group. Greater percentages of gastroesophageal reflux, allergic rhinitis, histories of asthma and acute bronchitis,
exposures to dusts and occupational exposures, and current smokers were seen in the CB + group. In multivariate
binomial logistic regression, male gender, Caucasian race, a lower FEV1%, allergic rhinitis, history of acute bronchitis,
current smoking, and increased airway wall thickness increased odds for having CB.
Conclusions: Histories of asthma, allergic rhinitis, acute bronchitis, current smoking, a lower FEV1%, Caucasian race,
male gender, and increased airway wall thickness are associated with CB. These data provide clinical and radiologic
correlations to the clinical phenotype of CB.
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Figure 1 Selection of cohort.
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Chronic bronchitis (CB) affects 18-45% of COPD subjects
and has been linked to multiple clinical sequelae including
an increased exacerbation rate, accelerated decline in lung
function, worse health-related quality of life (HRQoL), and
possibly increased mortality [1-3]. The pathologic correlate
to CB is goblet cell hyperplasia, which is well described in
both the large and small airways in COPD subjects [4,5].
Small airway mucus burden has been linked to mortality
and changes in lung function after lung volume reduction
surgery [6,7]. A large lung pathology study also found that
the number of small airways occluded by mucus plugs in-
creased as COPD disease severity worsened [8].
Despite the clinical importance of CB on outcomes, our
understanding of its pathophysiology is surprisingly poor.
It is unclear why some individuals develop chronic bron-
chitis whereas others do not, despite similar environmental
exposures. A thirty year longitudinal study found that 42%
of continued smokers, 26% of ex-smokers, and 22% of
never smokers developed CB [9]. To complicate matters,
the correlation between symptoms and goblet cell hyper-
plasia is poor, and the most well described pathologic index
of CB is weak at best [10]. An analysis of the National Em-
physema Treatment Trial found no relationship with the
severity of cough and sputum with small airway occlusion
by mucus [11]. Thus, a better understanding of chronic
bronchitis from a pathologic standpoint is needed.
An emerging surrogate for pathologic study is CT quan-
titative analysis of airway dimensions and emphysema.
From a clinical standpoint, we have shown that chronic
bronchitics in a group of 1,061 subjects from the COPD-
Gene study with moderate to severe airflow obstruction
were younger, more likely to be current smokers, male,
Caucasian, had worse health related quality of life, more
dyspnea, and increased exacerbation history compared to
those without CB [2]. We sought to further refine our
clinical characterization of chronic bronchitics in a larger
cohort, analyze the CT correlates of CB in COPD subjects,
and develop a prediction model for CB with these charac-
teristics. We hypothesized that subjects with CB would
have thicker airway walls, less emphysema, a greater per-
centage of current smoking, a greater overall history of
smoking, a greater exposure to environmental fumes and
dusts, and more allergic upper airway symptoms.
Methods
Patient selection
The Genetic Epidemiology of COPD (COPDGene®)
Study is a multicenter observational study that recruited
over 10,000 subjects to analyze genetic susceptibility for
the development of COPD. This study underwent IRB
approval at all centers. Inclusion and exclusion criteria
and protocol were described previously [12]. Briefly, enrol-
lees are African-American or non-Hispanic Caucasianbetween the ages of 45 and 80 with at least a 10 pack-year
smoking history. Exclusion criteria include pregnancy, his-
tory of other lung disease except asthma, prior lobectomy
or lung volume reduction, active cancer undergoing treat-
ment, or known or suspected lung cancer. We used the
March 2013 dataset with 10,192 subjects and included
those with GOLD 1 through 4 COPD that had complete
medical histories and quantitative CT assessments in our
analysis. Subjects from our prior analysis [2] were included
in this study.
Subjects were asked if they had cough; if they responded
yes, they were asked if they coughed on most days for 3
consecutive months or more each year and for how many
years. Similar questions were asked regarding phlegm pro-
duction. Subjects were placed in 1) the chronic bronchitis
group (CB+), if they had chronic cough and phlegm pro-
duction for 3 months or more each year for at least two
consecutive years; or 2) the no chronic bronchitis group
(CB-), if these criteria were not satisfied. Figure 1 demon-
strates the patient selection process.
Clinical characterization
Upper and lower respiratory tract symptoms were col-
lected using a modified form of the American Thoracic
Society Division of Lung Disease (ATS-DLD) Respiratory
Epidemiology questionnaire. Medical comorbidities and
occupational exposures were assessed based on subject
self-report. Of particular interest were histories of asthma,
episodes of acute bronchitis, allergic ocular and nasal
symptoms, exposures to gases and fumes (defined as occu-
pational exposures), exposures to dusts, and gastroesopha-
geal reflux disease. The definition of acute bronchitis was
determined by the answer to the question “Have you ever
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ally if they had these conditions and were instructed to an-
swer yes or no. Subjects that answered “don’t know” to
these questions were excluded from the analysis. Subjects
were also asked if they experienced COPD exacerbations
in the past year and to quantify the number of episodes,
and if they have been to the emergency room or hospi-
talized for an exacerbation in the past year (defined as
severe exacerbations). An exacerbation was defined as
a flare-up of chest trouble requiring treatment with an-
tibiotics and/or steroids. These answers were used to
determine exacerbation history and history of severe
exacerbations, respectively. Each subject underwent pre-
and post-bronchodilator spirometry using an EasyOne™
spirometer (Zurich, Switzerland). Predicted values were
obtained using NHANES III data. Six minute walk dis-
tance was measured in standard fashion [13].
Computed tomography
Volumetric chest CT acquisitions were obtained at full in-
spiration (200 mAs), and at the end of normal expiration
(50 mAs) [12]. Thin-slice collimation with slice thickness
and intervals of < lmm was used to enhance spatial reso-
lution. Quantitative image analysis to calculate percent
emphysema and percent gas-trapping was performed
using 3D SLICER (http://www.slicer.org/). Percent emphy-
sema was defined as the total percentage of both lungs
with attenuation values less than −950 Hounsfield units
on inspiratory images, and percent gas trapping was de-
fined as the total percentage of both lungs with attenu-
ation values less than −856 Hounsfield units on expiratory
images. Airway disease was quantified as wall area percent
(WA%: (wall area/total bronchial area)x100) using VIDA
(http://www.vidadiagnostics.com) [14]. The mean WA%
were calculated as the average of the values for six seg-
mental bronchi in each subject. Using 3D SLICER, airway
wall thickness was also expressed as the square root of the
wall area of a hypothetical 10 mm and 15 mm internal
perimeter airway (Pi10 and Pi15, respectively) as previ-
ously described [15].
Statistical analysis
Statistical analysis was performed using Stata 13. Values
are expressed as mean ± SD unless otherwise stated. CB +
was the outcome of interest. The covariates analyzed in
the model included gender, race, current smoking, smok-
ing history, gastroesophageal reflux, COPD severity based
on FEV1 and FVC, allergic eye and nasal symptoms, occu-
pational exposures, exposure to dusts, history of asthma,
history of acute bronchitis, and quantitative CT abnormal-
ities (Pi10, Pi15, WA% seg). To reduce multicollinearity,
principal axis factoring was used to estimate a wall thick-
ness composite. Multivariable logistic regression using a
trimmed covariate set selected via backward eliminationwith robust standard errors adjusting for within-clinic
clustering was used to predict CB with all covariates asso-
ciated with CB at p < .1 in at least one model retained.
Interactions between predictors of interest and sex and
race were considered in sensitivity analyses. All relevant as-
sumptions were evaluated in the usual fashion (e.g., linearity
of association, link tests, hat tests).Results
The patient characteristics and univariate analysis of the
groups are summarized in Table 1. There were a total of
4484 GOLD 1–4 subjects; of those with complete medical
history and quantitative CT analysis, there were 2703 sub-
jects, 2040 subjects in the CB- group and 663 in the CB +
group (24.5% of total). The CB + group was younger, had a
greater smoking history, and was more likely to be current
smokers, Caucasian, and male. The CB + group had a
lower forced expiratory volume in 1 second (FEV1), forced
vital capacity (FVC) and FEV1/FVC ratio. 6-minute walk
distance was lower and MMRC dyspnea and BODE scores
were higher in the CB + group as well. More subjects in
the CB + group described gastroesophageal reflux (relative
risk [RR] 1.2), allergic nasal and ocular symptoms (RRs 1.5
and 1.3, respectively), a history of asthma and acute bron-
chitis (RRs 1.4 and 1.3, respectively), and were more likely
to be exposed to dusts and occupational exposures (RRs
1.4 and 1.3, respectively). Total exacerbation rate in the
year prior to enrollment and history of severe exacerba-
tions were higher in the CB + group as well. In a multivari-
able linear regression with FEV1, FVC, race, gender,
mMRC dyspnea score, BMI, and CB as predictors of inter-
est, CB was a significant predictor exacerbation frequency
(β coefficient 0.295, p < 0.0001). The CB + group had a
greater mean segmental wall area percent, Pi10, and Pi15.
There were no differences in quantitative measures of per-
cent emphysema or percent gas trapping between groups.
To assess for the possible confounding effects of active
smoking, we performed a separate univariate analysis of
active smokers versus those that did not currently smoke
on the same variables. Active smokers walked a greater
distance in 6 minutes (1288.58 ± 390.69 vs. 1189.95 ±
415.72 feet, p < 0.0001), were less dyspneic (MMRC scores
1.69 ± 1.48 vs. 2.07 ± 1.43, p < 0.0001), had lower SGRQ
scores (36.07 ± 23.79 vs. 37.50 ± 22.22, p = 0.038), had bet-
ter lung function (FEV1 63.5 ± 21.3 vs. 52.7 ± 22.8%, FVC
85.9 ± 19.9 vs. 78.8 ± 20.2%. p < 0.0001 for both), and had
less emphysema and gas trapping (6.79 ± 8.83 vs. 15.25 ±
13.07% and 28.03 ± 18.88 vs. 41.58 ± 20.35%, respectively,
p < 0.0001 for both). Fewer active smokers described aller-
gic ocular or nasal symptoms, gastroesophageal reflux, or
severe exacerbations. Airway wall thickness, however, was
greater in active smokers, as measured by Pi10, Pi15, and
WA% segmental.
Table 1 Baseline characteristics and radiology
Chronic bronchitis (CB+) n = 663 No chronic bronchitis (CB-) n = 2040 p
Demographics and symptoms
Age (years) 61.8 ± 8.5 63.8 ± 8.5 <0.0001
Smoking history (pack years) 56.4 ± 26.8 50.7 ± 26.3 <0.0001
Current smokers (%) 59.2 37.4 <0.0001
Gender (%M) 64 55 <0.0001
Race (%C) 84 78 <0.0001
FEV1 (% predicted) 54.3 ± 20.7 60.1 ± 23.4 <0.0001
FVC (% predicted) 80.5 ± 19.9 84.0 ± 20.1 <0.0001
FEV1/FVC 0.51 ± 0.13 0.53 ± 0.14 <0.0001
6MWD (meters) 372 ± 118 392 ± 121 <0.0001
BMI (kg/m2) 27.3 ± 5.9 27.7 ± 5.8 0.144
BODE score 3.0 ± 2.0 2.3 ± 2.1 <0.0001
MMRC dyspnea 2.3 ± 1.4 1.6 ± 1.5 <0.0001
SGRQ score 48.0 ± 21.3 30.6 ± 21.8 <0.0001
Exposures and Medical History
Gastroesophageal reflux (%) 33.8 28.6 0.010
Allergic nasal symptoms (%) 69.5 47.0 <0.0001
Allergic ocular symptoms (%) 51.0 37.9 <0.0001
History of asthma (%) 33.4 23.4 <0.0001
History of bronchitis (%) 66.0 49.8 <0.0001
Exposure to dusts (%) 64.7 47.4 <0.0001
Occupational exposures (%) 65.6 51.0 <0.0001
Exacerbations
Total exac rate (no./pt/yr) 0.96 ± 1.46 0.52 ± 1.04 <0.0001
History of severe Exac (%) 24.2 15.2 <0.0001
Radiology
% Emphysema (%) 11.4 ± 12.0 12.0 ± 12.6 0.347
% Gas trapping (%) 35.3 ± 21.2 36.3 ± 20.6 0.272
Mean segmental WA% (%) 63.0 ± 3.2 62.0 ± 3.1 <0.0001
Pi10 (mm) 3.72 ± 0.15 3.69 ± 0.14 <0.0001
Pi15 (mm) 5.24 ± 0.22 5.17 ± 0.20 <0.0001
Definition of abbreviations: M =male, F = female, C = Caucasian, AA = African American, FEV1 = forced expiratory volume in 1 second, FVC = forced vital capacity,
6MWD = 6-minute walk distance, Exac = exacerbation, BMI = body mass index.
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Principal axis factoring was used to reduce collinearity in
wall area thickness measures. Two factors accounted for
essentially 100% of the shared variance among wall area
thickness measures, and each item loaded highly on only
one factor. The rotated pattern matrix is shown in Table 2.
Quartimax rotated factor scores were constructed using
the regression method and agreed well (r > .99) with prin-
cipal components results.
Table 3 summarizes the multivariate binomial logistic
regression of the predictors of interest with chronic bron-
chitis as the outcome. In this multivariate analysis, there
was no independent association between smoking historyor occupational exposures and chronic bronchitis. Female
gender and African American race were associated with
lower odds ratios of CB (OR 0.68, 95% CI 0.59-0.79, and
OR 0.57, 95% CI 0.43-0.76, respectively). Lower FEV1 and
higher FVC were associated with a greater risk of CB
(ORs 0.84, 95% CI 0.78-0.90 and 1.10, 95% CI 1.00-1.21,
respectively, per 10% increase). The ORs for allergic ocular
symptoms, allergic nasal symptoms, history of asthma,
history of acute bronchitis, gastroesophageal reflux, and
current smoking were 1.17, 2.11, 1.38, 1.65, 1.16, and 3.53,
respectively (see Table 3 for 95% CIs). A composite value
of the three CT airway variables (called wall thickness)
conferred an OR of 1.19 (95% CI 1.02-1.37) for chronic
Figure 2 Odds ratios for chronic bronchitis.
Table 2 Quartimax rotated factor pattern matrix
Variable WA thickness Emphysema Uniqueness
ln % Emph −0.1199 0.8883 0.1965
% Gas trap 0.0561 0.8916 0.2019
Pi10 0.6983 0.0327 0.5114
Pi15 0.8393 −0.1173 0.2819
WA% seg 0.8533 0.0224 0.2714
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tors of interest.
As an additional set of sensitivity analyses, we consid-
ered potential interactions between each predictor of
interest with sex and race for each predictor of interest
separately and when entered as a group. None of the
interaction terms remained significant after adjustment
for multiple hypothesis tests. Figure 3 shows the receiver
operator curve for all of the aforementioned predictors
of interest in the model for chronic bronchitis as the
outcome. The area under the curve is 0.75.
Discussion
We showed in a large cohort of 2,703 COPD subjects that
chronic bronchitics were younger, had a reduced 6-minute
walk distance, had a greater exacerbation frequency, were
more likely to have gastroesophageal reflux, allergic ocular
and nasal symptoms, histories of asthma and bronchitis,
and were more likely to be current smokers, Caucasian,
and male compared to those without CB, thereby validat-
ing our prior clinical findings in a smaller cohort that was
less well characterized from a radiographic standpoint [2].
These findings were independent of the presence of active
smoking. We also showed that the CB + group had aTable 3 Odds ratios for chronic bronchitis in a
multivariate logistic regression model
OR 95% CI p
Wall thickness 1.19 1.02 1.37 0.022
Female gender 0.68 0.59 0.79 <0.0001
African American race 0.57 0.43 0.76 <0.0001
FEV1 (per 10% predicted) 0.84 0.78 0.90 <0.0001
FVC (per 10% predicted) 1.10 1.00 1.21 0.043
Allergic ocular symptoms 1.17 0.97 1.42 0.105
Allergic nasal symptoms 2.11 1.81 2.46 <0.0001
History of asthma 1.38 1.14 1.67 0.001
History of bronchitis 1.65 1.41 1.94 <0.0001
Gastroesophageal reflux 1.16 0.98 1.39 0.092
Current smoking 3.53 2.72 4.58 <0.0001
Smoking history (pack years) 1.004 1.003 1.007 0.035
Exposure to dusts 1.62 1.19 2.20 0.002
Occupational exposures 1.00 0.81 1.25 0.996greater segmental wall area percent, Pi10, and Pi15 despite
similar degrees of emphysema and gas trapping. Finally,
we showed that the variables independently associated
with CB were lung function, allergic rhinitis symptoms,
history of acute bronchitis and asthma, airway wall thick-
ness, exposure to dusts, gender, race, and current smoking
in multivariate analysis. Using our prediction model, one
can help identify those with the clinical phenotype of CB
that is at higher risk for poor outcomes. To our know-
ledge, this is the first analysis that combines quantitative
CT and clinical variables as predictors of CB in a large co-
hort of COPD subjects.
CB affects approximately 10 million individuals in the
United States, and the majority are between 44 and
65 years of age [16]. CB has been associated with numer-
ous adverse clinical outcomes. Exacerbation frequency has
been shown to be greater in patients with COPD and CB
in several studies [3,17]. Seemungal et al. found that CBFigure 3 ROC curve for chronic bronchitis using all predictors
of interest in the final model.
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bations in a group of 70 patients [17]. A cross-sectional
analysis of 433 patients also similarly found an increased
risk of exacerbation among individuals with CB [3].
CB may increase all-cause mortality as well, independ-
ent of the level of airflow obstruction. Some but not all
studies have shown CB to be an independent risk factor
for death. In a study by Pelkonen et al., the multivariable
hazard ratios for all-cause mortality in those with per-
sistent CB was 1.64 (95% CI, 1.23–2.19) after adjustment
for lung function [9]. In a post hoc analysis of the Na-
tional Emphysema Treatment Trial, severe CB, defined
as chronic cough, phlegm, and chest trouble, was associ-
ated with a higher mortality and hospitalization rate in
those treated with medical therapy alone [18]. CB has
also been shown to hasten the rate of lung function de-
cline and reduce health related quality of life [2,19,20].
Radiographic characterization of COPD has been per-
formed extensively in the past, [17,18,21] but few studies
have related CT parameters to the clinical phenotype of
CB. A small study of 42 COPD subjects showed that air-
way wall thickness was greater in those with CB compared
to those without [22]. We have shown that percent emphy-
sema and percent gas trapping were no different between
those with CB and those without in 1061 moderate to se-
vere COPD subjects [2]. We validate these prior findings
on our study but add quantitative airway measurements in
several compartments. Our findings of increased mean
segmental wall area percent, Pi10, and Pi15 (“medium
sized airways”) in chronic bronchitics is consistent with the
notion that the clinical phenomenon of chronic bronchitis
arises from mucus hypersecretion from larger more prox-
imal airways, as opposed to small airway disease which is
often difficult to detect clinically [11,23]. This is, however,
hypothesis generating and would require further study for
confirmation. Although the differences in WA% were small,
the composite variable of wall thickness was significantly
associated with CB.
One of the strongest predictors of CB in this cohort was
current smoking. Smoking causes airway inflammation and
oxidative stress which induces mucin gene expression [1].
Active smokers have been shown in other studies to be at
greater risk of CB. In a 30-year longitudinal study of 1,711
Finnish men, the cumulative incidence of CB was 42% in
continuous smokers, 26% in ex-smokers, and 22% in never
smokers [9]. A recent metaanalysis found that among 101
studies, ever smoking and current smoking were associated
with relative risks of 2.69 and 3.41, respectively, for CB
[24]. We showed that current smoking was associated with
an odds ratio of 3.53 for CB.
Although the primary risk factor for CB is smoking, it
should be noted that CB has been described in up to 22%
of never smokers, [9] suggesting that other risk factors
may exist. Other potential risk factors include inhalationalexposures to biomass fuels, dusts, and chemical fumes
[25,26]. A survey of South African adults found occupa-
tional exposure to be a risk factor for CB in men (OR 2.6;
95% CI 1.7–4.0) and domestic fuel exposure to be a risk
factor for CB in women (OR, 1.9; 95% CI 1.4–2.6) [27]. In
a recent analysis of 5,858 smokers or ex-smokers without
COPD, patients with CB were more likely to have been ex-
posed to fumes at work (76.4 vs. 60.9%, P < 0.001) or to
have worked more than 1 year at a dusty job (76 vs. 57%,
P < 0.001) [28]. We found that subjects with CB had a 1.4-
fold and 1.3-fold increased risk for exposure to dusts and
occupational exposures, respectively. Although occupa-
tional exposures were not statistically significant in the
multivariate predictive model, we present some evidence
of their association in univariate analysis, providing more
evidence of a causal association.
Another potential risk factor for CB is the presence of
gastroesophageal reflux disease (GERD), possibly by pul-
monary aspiration of refluxed gastric contents producing
acid-induced injury and infection or neurally mediated re-
flex bronchoconstriction secondary to irritation of esopha-
geal mucosa [29]. There is increasing evidence that not
only is GERD a significant comorbidity but also that it is a
risk factor for COPD related outcomes. For example, the
Evaluation of COPD Longitudinally to Identify Predictive
Surrogate Endpoints (ECLIPSE) study identified GERD as
a risk factor for COPD exacerbations in longitudinal
follow-up [30]. In the Azithromycin for Prevention of Ex-
acerbations of COPD (MACRO) trial, GERD was associ-
ated with an increased risk of COPD exacerbations [31].
In our study, we demonstrated that GERD was more com-
mon in those with CB and that GERD conferred a slightly
increased odds ratio of having CB in multivariate analysis
that almost reached statistical significance.
Other risk factors identified in our study include a his-
tory of acute bronchitis, and allergic nasal symptoms. Re-
peated bouts of acute bronchitis has been considered a
risk factor for the development of CB, [32] possibly by the
development of persistent inflammation and mucus hyper-
secretion after multiple episodes of infectious bronchitis.
Mucus hypersecretion is a signature pathologic feature of
asthma, and asthma’s association with allergic rhinitis is
strong. The association between chronic bronchitis and al-
lergic nasal symptoms suggests a link between upper and
lower airway inflammation that has commonly been de-
scribed in asthma. This raises the possibility of a common
pathophysiology between CB and asthma, which deserves
further attention.
The influence of gender on CB continues to be a matter
of debate. Many studies have found that CB affects men
more than women, [2,33,34] but in the 2009 National
Center for Health Statistics report, 67.8% of patients with
CB were women [35]. The reasons for the higher preva-
lence of CB in women compared with men is unclear, but
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symptom reporting, and sex diagnostic bias. Our study
showed that men were more likely to be affected by CB
and that gender was an independent predictor of CB in
multivariate analysis.
Despite the clinical and CT findings in this robust co-
hort of unselected COPD subjects, there are several limi-
tations that are worthy of mention. First, the assessment
of medical history and exposures was by self-report, po-
tentially leading to recall bias. The outcome of interest it-
self is somewhat subjective as well (chronic cough and
phlegm). Although the identified clinical and computed
tomographic factors were used in a prediction model, one
could argue that some of predictors of interest are caused
by chronic bronchitis, not the result of it (eg, airway wall
thickness). In addition, it is unclear why the FVC is lower
in chronic bronchitics in univariate analysis but higher in
multivariate analysis; this phenomenon is most likely due to
the confounding factors of differences in FEV1, race, and
gender. However, the predictors of interest were chosen be-
cause of the more likely causal relationship of CB. Nonethe-
less, our analysis offers a comprehensive characterization of
chronic bronchitis in COPD as well as a prediction model
for CB using several clinical and computed tomographic
parameters.
Conclusions
In conclusion, we show that allergic rhinitis, acute bron-
chitis, asthma, male gender, Caucasian race, lung function,
current smoking, and airway wall thickness are associated
with clinical phenotype of CB. We also show in a large
cohort that CB is associated with greater exacerbation fre-
quency, worse health related quality of life, and a lower 6-
minute walk distance. Identification of these clinical and
CT parameters can help predict the clinical phenotype of
CB and can help stratify patients into a group at higher
risk for poor outcomes. This group should receive treat-
ment for their comorbidities and receive targeted therapy
towards smoking cessation.
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